IHC analyses in our 22 cases of HER2+ BC confirmed that tumors from patients that remained disease-free following anti-HER2 mAbs treatment showed an increased number of intra-tumoral CD56+ immune cells (NK cells) compared to tumors from relapsing patients (Fig. 3e, Supplementary Fig. 2b). This evidence concerns the gene ERBB2 and breast cancer.